Effect of doxycycline on atherosclerosis: From bench to bedside

Recent Patents on Cardiovascular Drug Discovery

Volumn 6, Issue 1, 2011, Pages 42-54

  Rodriguez Granillo, Gastón A ^a,b,c   Rodriguez Granillo, Agustina ^d,e   Milei, José ^a  

^a UBA CONICET ^*  (Argentina)

^b Sanatorio Otamendi y Miroli   (Argentina)

^c CABA   (Argentina)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^e Cardiovascular Research Center (CECI)   (Argentina)

Author keywords

Apo e deficient mice; Atherothrombosis; Coronary; Inflammation; Metalloproteinase; Mmp inhibitor; Remodeling

Indexed keywords

C REACTIVE PROTEIN; DOXYCYCLINE; DOXYCYCLINE HYCLATE; GELATINASE A; GELATINASE B; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; PLACEBO; STROMELYSIN 2;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; DRUG ABSORPTION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME STRUCTURE; EXTRACELLULAR MATRIX; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; DOXYCYCLINE; EVIDENCE-BASED MEDICINE; HUMANS; MATRIX METALLOPROTEINASES; PATENTS AS TOPIC; PROTEASE INHIBITORS; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

EID: 79551661715     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489011794578419     Document Type: Article

References (221)

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part II: Variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001; 104(23): 2855-2864.
2. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to moderate coronary artery disease? Circulation 1988; 78(5 Pt 1): 1157-1166.
3. [No authors listed] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-1389.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335(14):1001-1009.
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339(19): 1349-1357.
6. Kannel WB, Doyle JT, McNamara PM, Quickenton P, Gordon T. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation 1975; 51(4): 606-613.
7. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92(3): 657-671.
8. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001; 285(13): 1711-1718.
9. Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol 2010; 55(24): 2736-2742.
10. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005; 85(1): 1-31.
11. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Ann Rev Cell Dev Biol 2001; 17: 463-516.
12. Overall CM, Kleifeld O. Tumour microenvironment - opinion: Validating matrix metalloproteinases as drug targets and antitargets for cancer therapy. Nat Rev Cancer 2006; 6(3): 227-239.
13. Rodriguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: What do they not do? New substrates and biologicalroles identified by murine models and proteomics. Biochim Biophys Acta 2010; 1803(1): 39-54.
14. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: Regulators of the tumor micro environment. Cell 2010; 141(1): 52-67.
15. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003; 92(8): 827-839.
16. McCawley LJ, Matrisian LM. Matrix metalloproteinases: They're not just for matrix anymore. Curr Opin Cell Biol 2001; 13(5): 534-540.
17. Overall CM. Dilating the degradome: Matrix metalloproteinase 2 (MMP-2) cuts to the heart of the matter. Biochem J 2004; 383(Pt.3): e5-e7.
18. Whittaker M, Floyd CD, Brown P, Gearing AJ. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999; 99(9): 2735-2776.
19. Puerta DT, Cohen SM. A bioinorganic perspective on matrix metalloproteinase inhibition. Curr Top Med Chem 2004; 4(15):1551-1573.
20. Bertini, I, Calderone V, Fragai M, Giachetti A, Loconte M, Luchinat C, et al. Exploring the subtleties of drug-receptor interactions: The case of matrix metalloproteinases. J Am ChemSoc 2007; 129(9): 2466-2475.
21. Lauer-Fields J, Brew K, Whitehead JK, Li S, Hammer RP, Gregg B. Triple-helical transition state analogues: A new class of selective matrix metalloproteinase inhibitors. J Am Chem Soc 2007; 129(34): 10408-10417.
22. Golub LM, Lee H-M, Ryan ME, Ryan ME, Payne J, Sorsa T, et al. Tetracyclines inhibit connective tissue breakdown by multiple nonantimicrobial mechanisms. Adv Dent Res 1998; 12(2): 12-26.
23. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004; 9(1): 63-79.
24. Pirard B. Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug Discov Today 2007; 12(15-16): 640-646.
25. Hu J, Van den Steen PE, Sang QA, Opdenakker G. Matrimetalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6(6): 480-498.
26. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat Rev Cancer 2002; 2(9): 657-672.
27. Coussens LM, Fingleton B, Matrisian LM, Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295(5564): 2387-2392.
28. Mackay AR, Gomez DE, Nason AM, Thorgeirsson UP. Studies on the effects of laminin, E-8 fragment of laminin and synthetic laminin peptides PA22-2 and YIGSR on matrix metalloproteinases and tissue inhibitor of metalloproteinase expression. Lab Invest 1994; 70(6): 800-806.
29. Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 1996; 93(18): 9748-9753.
30. Overall CM. Molecular determinants of metalloproteinase substrate specificity: Matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol 2002; 22(1): 51-86.
31. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69(3): 562-573.
32. Maskos K. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie 2005; 87(3-4): 249-263.
33. Van Wart HE, Birkedal-Hansen H. The cysteine switch: A principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990; 87(14): 5578-5582.
34. Loftus IM, Naylor AR, Bell PR, Thompson MM. Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 2002; 89(6): 680-694.
35. Proudfoot D, Skepper JN, Weissberg PL, Shanahan CM. Acetylated low-density lipoprotein stimulates human vascular smooth muscle cell calcification by promoting osteoblastic differentiation and inhibiting phagocytosis. Circulation 2002; 106(24): 3044-3050.
36. Timpl R. Macromolecular organization of basement membranes. Curr Opin Cell Biol 1996; 8(5): 618-624.
37. Woods A, Oh ES, Couchman JR. Syndecan proteoglycans and cell dhesion. Matrix Biol 1998; 17(7): 477-483.
38. Thyberg J, Blomgren K, Roy J, Tran PK, Hedin U. Phenotypic modulation of smooth muscle cells after arterial injury is associated with changes in the distribution of laminin and fibronectin. J Histochem Cytochem 1997; 45(6): 837-846.
39. Zalewski A, Shi Y, Johnson AG. Diverse origin of intimal cells: Smooth muscle cells, myofibroblasts, fibroblasts, and beyond? Circ Res 2002; 91(8): 652-655.
40. Newby AC. Vitronectin is implicated as the matrix takes control of neointima formation. Cardiovasc Res 2002; 53(4): 779-781.
41. Wight TN. The extracellular matrix and atherosclerosis. Curr Opin Lipidol 1995; 6(5): 326-34.
42. Clowes AW, Clowes MM, Reidy MA. Kinetics of cellular proliferation after arterial injury. III. Endothelial and smooth muscle growth in chronically denuded vessels. Lab Invest 1986; 54(3): 295-303.
43. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340(2): 115-126.
44. Stary HC. The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J 1990; 11 (Suppl E): 3-19.
45. Libby P. Atherosclerosis: Disease biology affecting the coronary vasculature. Am J Cardiol 2006; 98(12A): 3Q-9Q.
46. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20(5): 1262-1275.
47. Arbustini E, Grasso M, Diegoli M, Morbini P, Aguzzi A, Fasani R, et al. Coronary thrombosis in non-cardiac death. Coron Artery Dis 1993; 4(9): 751-759.
48. Mann J, Davies MJ. Mechanisms of progression in native coronary arery disease: Role of healed plaque disruption. Heart 1999; 82(3): 265-268.
49. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J, et al. Healed plaque ruptures and sudden coronary death: Evidence that sub-clinical rupture has a role in plaque progression. Circulation 2001; 103(7): 934-940.
50. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69(5): 377-381.
51. Gertz SD, Roberts WC. Hemodynamic shear force in rupture of coronary arterial atherosclerotic plaques. Am J Cardiol 1990; 66(19): 1368-1372.
52. Davies MJ. The pathophysiology of acute coronary syndromes. Heart 2000; 83(3): 361-366.
53. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nat Med 2002; 8(11): 1257-1262.
54. Opdenakker G, Fibbe WE, Van Damme J. The molecular basis of leukocytosis. Immunol Today 1998; 19(4): 182-189.
55. Pruijt JF, Fibbe WE, Laterveer L, Pieters RA, Lindley IJD, Paemen L, et al. Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc Natl Acad Sci USA 1999; 96(19): 10863-10868.
56. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4(8): 617-629.
57. Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 2006; 12(6): 657-664.
58. Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, López-Boado YS, Stratman JL, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999; 286(5437): 113-117.
59. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000; 96(8): 2673-2681.
60. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM, et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000; 289(5482): 1202-1206.
61. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 2002; 100(4): 1160-1167.
62. Van Den Steen PE, Wuyts A, Husson SJ, Proost P, Van Damme J, Opdenakker G. Gelatinase B/MMP-9 and neutrophil collagenase/ MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem 2003; 270(18): 3739-3749.
63. Nelissen I, Martens E, Van den Steen PE, Proost P, Ronsse I, Opdenakker G, et al. Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy. Brain 2003; 126(Pt 6): 1371-1381.
64. McQuibban GA, Butler GS, Gong J-H, Bendall L, Power C, Clark-Lewis I, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001; 276(47): 43503-43508.
65. Libby P, Lee RT. Matrix matters. Circulation 2000; 102(16): 1874-1876.
66. Rodriguez JA, Orbe J, Paramo JA. Metalloproteases, vascular remodeling and atherothrombotic syndromes. Rev Esp Cardiol 2007; 60(9): 959-967.
67. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94(6): 2493-2503.
68. Nikkari ST, O'Brien KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE, et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995; 92(6): 1393-1398.
69. Nikkari ST, Geary RL, Hatsukami T, Ferguson M, Forough R, Alpers CE, et al. Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinases-1 in restenosis after carotid endarterectomy. Am J Pathol 1996; 148(3): 777-783.
70. Sukhova GK, Schonbeck U, Rabkin E. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99(19): 2503-2509.
71. Higashikata T, Yamagishi M, Higashi T, Nagata I, Iihara K, Miyamoto S, et al. Altered expression balance of matrix metalloproteinases and their inhibitors in human carotid plaque disruption: Results of quantitative tissue analysis using real-time RT-PCR method. Atherosclerosis 2006; 185(1): 165-72.
72. Yu Y, Koike T, Kitajima S, Liu E, Morimoto M, Shiomi M, et al. Temporal and quantitative analysis of expression of metalloproteinases (MMPs) and their endogenous inhibitors in atherosclerotic lesions. Histol Histopathol 2008; 23(12): 1503-15016.
73. Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT, et al. Increased expression of 72-kD type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 1996; 148(1): 121-128.
74. Kieffer P, Giummelly P, Schjoth B, Carteaux JP, Villemot JP, Hornebeck W, et al. Activation of metalloproteinase-2, loss of matrix scleroprotein content and coronary artery calcification. Atherosclerosis 2001; 157(1): 251-254.
75. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991; 88(18): 8154-8158.
76. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinasesinduced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann NY Acad Sci 1995; 748: 501-507.
77. Molloy KJ, Thompson MM, Jones JL, Schwalbe EC, Bell PRF, Naylor AR, et al. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 2004; 110(3): 337-343.
78. Sluijter JP, Pulskens WPC, Schoneveld AH, Velema E, Strijder CF, Moll F, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: A study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 2006; 37(1): 235-239.
79. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91(8): 2125-2131.
80. Montero I, Orbe J, Varo N, Beloqui O, Monreal JI, Rodríguez JA, et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: Implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006; 47(7): 1369-1378.
81. Schonbeck U, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M, et al. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med 1999; 189(5): 843-853.
82. Morgan AR, Rerkasem K, Gallagher PJ, Zhang B, Morris GE, Calder PC, et al. Differences in matrix metalloproteinase-1 and matrix metalloproteinase-12 transcript levels among carotid atherosclerotic plaques with different histopathological characteristics. Stroke 2004; 35(6): 1310-1305.
83. Rajavashisth TB, Xu X-P, Jovinge S, Meisel S, Xu X-O, Chai N-N, et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: Evidence for activation by proinflammatory mediators. Circulation 1999; 99(24): 3103-3109.
84. Johnson JL, Sala-Newby GB, Ismail Y, Aguilera CM, Newby AC. Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol 2008.
85. Uzui H, Harpf A, Liu M, Doherty TM, Shukla A, Chai NN, et al., Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: Role of activated macrophages and inflammatory cytokines. Circulation 2002; 106(24): 3024-3030.
86. Herman MP, Sukhova GK, Kisiel W, Foster D, Kehry MR, Libby P, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001; 107(9): 1117-1126.
87. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316(22): 1371-1375.
88. Pasterkamp G, Schoneveld AH, van der Wal AC, Haudenschild CC, Clarijs RJG, Becker AE, et al. Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: The remodeling paradox. J Am Coll Cardiol 1998; 32(3): 655-662.
89. Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation 2002; 105(8): 939-943.
90. Burke AP, Kolodgie FD, Farb A, Weber D, Virmani R. Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation 2002; 105(3): 297-303.
91. Rodriguez-Granillo GA, Serruys PW, Garcia-Garcia HM, Aoki J, Valgimigli M, van Mieghem CAG, et al. Coronary artery remodeling is related to plaque composition. Heart 2006; 92(3): 388-391.
92. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 2002; 90(3): 251-262.
93. Rodriguez-Granillo GA, de Winter S, Bruining N, Ligthart JMR, García-García1 HM, Valgimigli M, et al. Effect of perindopril on coronary remodelling: Insights from a multicentre, randomized study. Eur Heart J 2007; 28(19): 2326-2331.
94. Terashima M, Akita H, Kanazawa K, Inoue N, Yamada S, Ito K, et al. Stromelysin promoter 5A/6A polymorphism is associatedwith acute myocardial infarction. Circulation 1999; 99(21): 2717-2719.
95. Ghaderian SM, Najar AR, Panah TAS. Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coronary Artery Dis 2010; 21(6): 330-335.
96. Roman-Garcia P, Coto E, Reguero JR, Cannata-Andia JB, Lozano I, Avanzas P, et al. Matrix metalloproteinase 1 promoter polymorphisms and risk of myocardial infarction: A case-control study in a Spanish population. Coronary Artery Dis 2009; 20(6): 383-386.
97. Liu PY, Li YH, Chan SH, Lin LJ, Wu HL, Shi GY, et al. Genotype-phenotype association of matrix metalloproteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome. Am J Cardiol 2006; 98(8): 1012-1017.
98. Abilleira S, Bevan S, Markus HS. The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J Med Genet 2006; 43(12): 897-901.
99. Laxton RC, Hu Y, Duchene J, Zhang F, Zhang Z, Leung KY, et al. A role of matrix metalloproteinase-8 in atherosclerosis. Circulation Res 2009; 105(9): 921-929.
100. Cheng C, Tempel D, van Haperen R, van Damme L, Algur M, Krams R, et al. Activation of MMP8 and MMP13 by angiotensin II correlates to severe intra-plaque hemorrhages and collagen breakdown in atherosclerotic lesions with a vulnerable phenotype. Atherosclerosis 2009; 204(1): 26-33.
101. Newby AC. Do metalloproteinases destabilize vulnerable atherosclerotic plaques? Curr Opin Lipidol 2006; 17(5): 556-561.
102. Prescott MF, Sawyer WK, Von Linden-Reed J, Jeune M, Chou M, Caplan SL, et al. Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptordeficientmice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury. Ann NY Acad Sci 1999; 878: 179-190.
103. Johnson JL, Fritsche-Danielson R, Behrendt M, Westin-Eriksson A, Wennbo H, Herslof M, et al. Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc Res 2006; 71(3): 586-595.
104. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003; 59(4): 812-823.
105. Ardans JA, Blum A, Mangan PR, Wientroub S, Cannon RO, Wahl LM, et al. Raloxifene-mediated increase in matrix metalloproteinase-1 production by activated monocytes. Arterioscler Thromb Vasc Biol 2001; 21(8): 1265-1268.
106. Silence J, Collen D, Lijnen HR. Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res 2002; 90(8): 897-903.
107. Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 2001; 21(9): 1440-1445.
108. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark MW, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75(1): 181-189.
109. Galis ZS, Kranzhöfer R, Fenton JW, Libby P. Thrombin promotes activation of matrix metalloproteinase-2 produced by culturedvascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17(3): 483-489.
110. Duhamel-Clerin E, Orvain C, Lanza F, Cazenave JP, Klein-Soyer C. Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17(10): 1931-1938.
111. Jormsjo S, Ye S, Moritz J, Walter DH, Dimmeler S, Zeiher AM, et al. Allele-specific regulation of matrix metallo-proteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 2000; 86(9): 998-1003.
112. Siwik DA, Chang DL, Colucci WS. Interleukin-1beta and tumornecrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000; 86(12): 1259-1265.
113. Feinberg MW, Jain MK, Werner F, Sibinga NE, Wiesel P, Wang H, et al. Transforming growth factor-beta 1 inhibits cytokinemediated induction of human metalloelastase in macrophages. J Biol Chem 2000; 275(33): 25766-25773.
114. Arenas IA, Xu Y, Lopez-Jaramillo P, Davidge ST. Angiotensin IIinduced MMP-2 release from endothelial cells is mediated by TNFalpha. Am J Physiol Cell Physiol 2004; 286(4): C779-C784
115. Williams TN, Zhang CX, Game BA, He L, Huang Y. C-Reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal-regulated kinase pathway: An implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol 2004; 24(1): 61-66.
116. Orbe J, Montero I, Rodríguez JA, Beloqui O, Roncal C, Páramo JA, et al. Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis. J Thromb Haemost 2007; 5(1): 91-97.
117. Liang J, Liu E, Yu Y, Kitajima S, Koike T, Jin Y, et al. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation 2006; 113(16): 1993-2001.
118. Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci USA 1996; 93(9): 3942-3946.
119. Wang X, Liang J, Koike T, Sun H, Ichikawa T, Kitajima S, et al. Overexpression of human matrix metalloproteinase-12 enhances the development of inflammatory arthritis in transgenic rabbits. Am J Pathol 2004; 165(4): 1375-1383.
120. Fan J, Wang X, Wu L, Matsumoto SI, Liang J, Koike T, et al. Macrophage-specific overexpression of human matrix metalloproteinase-12 in transgenic rabbits. Transgenic Res 2004; 13(3): 261-269.
121. Warner RL, Lukacs NW, Shapiro SD, Bhagarvathula N, Nerusu KC, Varani J, et al. Role of metalloelastase in a model of allergiclung responses induced by cockroach allergen. Am J Pathol 2004; 165(6): 1921-1930.
122. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 2005; 102(43): 15575-15580.
123. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994; 75(3): 539-545.
124. Zempo N, Kenagy RD, Au YP, Bendeck M, Clowes MM, Reidy MA, et al. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg 1994; 20(2): 209-217.
125. Southgate KM, Fisher M, Banning AP, Thurston VJ, Baker AH, Fabunmi RP, et al. Up regulation of basement membrane-degradingmetallo proteinase secretion after balloon injury of pig carotid arteries. Circ Res 1996; 79(6): 1177-1187.
126. Kenagy RD, Vergel S, Mattsson E, Bendeck M, Reidy MA, Clowes AW, et al. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. Arterioscler Thromb Vasc Biol 1996; 16(11): 1373-1382.
127. Aoyagi M, Yamamoto M, Azuma H, Nagashima G, Niimi Y, Tamaki M, et al. Immunolocalization of matrix metalloproteinases in rabbit carotid arteries after balloon denudation. Histochem Cell Biol 1998; 109(2): 97-102.
128. Lijnen HR, Lupu F, Moons L, Carmeliet P, Goulding D, Collen D, et al. Temporal and topographic matrix metalloproteinase expression after vascular injury in mice. Thromb Haemost 1999; 81(5): 799-807.
129. Godin D, Ivan E, Johnson C, Magid R, Galis ZS. Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation 2000; 102(23): 2861-2866.
130. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 2006; 69(3): 614-624.
131. Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A, et al. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26(5): 1120-112.
132. Luttun A, Lutgens E, Manderveld A, Maris K, Collen D, Carmeliet P, et al. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004; 109(11): 1408-1414.
133. Pasterkamp G, Schoneveld AH, Hijnen DJ, de Kleijn DP, Teepen H, van der Wal AC, et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000; 150(2): 245-253.
134. Thompson RW, Parks WC. Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann NY Acad Sci 1996; 800: 157-174.
135. Knox JB, Sukhova GK, Whittemore AD, Libby P. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 1997; 95(1): 205-212.
136. Rodriguez-Granillo GA, García-García HM, Valgimigli M, Vaina S, van Mieghem C, van Geuns RJ, et al. Global characterization of coronary plaque rupture phenotype using three-vessel intravascular ultrasound radiofrequency data analysis. Eur Heart J 2006; 27(16): 1921-1927.
137. Rodriguez-Granillo GA, García-García HM, McFadden EP, Valgimigli M, Aoki J, de Feyter P, et al. In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol 2005; 46(11): 2038-2042.
138. Shah PK, Galis ZS. Matrix metalloproteinase hypothesis of plaque rupture: Players keep piling up but questions remain. Circulation 2001; 104(16): 1878-1880.
139. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32(2): 368-372.
140. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K, et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141(2): 211-217
141. Ferroni P, Basili S, Martini F, Cardarello CM, Ceci F, Di Franco M, Bertazzoni G, et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: A novel marker of inflammation. J Investig Med 2003; 51(5): 295-300.
142. Loftus IM, Goodall S, Crowther M, Jones L, Bell PRF, Naylor AR, et al. Increased MMP-9 activity in acute carotid plaques: Therapeutic avenues to prevent stroke. Ann NY Acad Sci 1999; 878: 551-554.
143. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 2000; 31(1): 40-47.
144. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107(12): 1579-8155.
145. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-court D, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: Mechanisms for inflammatory damage in chronic disorders? QJM 2002; 95(12): 787-796.
146. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 2006; 151(5): 1101. e1-e8.
147. Dorman G, Cseh S, Hajdu I, Barna L, Konya D, Kupai K, et al. Matrix metalloproteinase inhibitors: A critical appraisal of design principles and proposed therapeutic utility. Drugs 2010; 70(8): 949-964.
148. Overall CM, Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006; 94(7): 941-946.
149. Bertini I, Calderone V, Cosenza M, Fragai M, Lee Y-M, Luchinat C, et al. Conformational variability of matrix metalloproteinases: Beyond a single 3D structure. Proc Natl Acad Sci USA 2005; 102(15): 5334-5339.
150. Acharya MR, Figg VJ, Sparreboom A. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist Updat 2004; 7(3): 195-208.
151. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991; 2(3): 297-321.
152. Ramamurthy NS, Rifkin BR, Greenwald RA, Xu JW, Liu Y, Turner G, et al. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: A comparison of 6 chemically modified tetracyclines. J Periodontol 2002; 73(7): 726-734.
153. Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL- 3) in a metastatic prostate cancer model. Int J Cancer 2002; 98(2): 297-309.
154. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong WV. Targeting leukocyte MMPs and transmigration: Minocycline as a potential therapy for multiple sclerosis. Brain 2002; 125(Pt 6): 1297-308.
155. Zernicke RF, Wohl GR, Greenwald RA, Moak SA, Leng W, Golub LM, et al. Administration of systemic matrix metalloproteinase inhibitors maintains bone mechanical integrity in adjuvant arthritis. J Rheumatol 1997; 24(7): 1324-1331.
156. Turk B. Targeting proteases: Successes, failures and future prospects. Nat Rev Drug Discov 2006; 5(9): 785-799.
157. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007; 13(3): 333-346.
158. Fingleton B. MMPs as therapeutic targets--still a viable option? Semin Cell Dev Biol 2008; 19(1): 61-68.
159. Viera MH, Perez OA, Berman B. Incyclinide. Drugs Future 2007; 32(3): 209-214.
160. Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, et al. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res 2007; 13(7): 2091-2099.
161. Yamada H, Watanabe K, Saito T, Hayashi H, Niitani Y, Kikuchi T, et al. Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its prodrug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis. J Rheumatol 1999; 26(3): 654-662.
162. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: Role in arthritis. Front Biosci 2006;11: 529-543.
163. Smith GN, Jr., Mickler EA, Hasty KA, Brandt KD. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: Relationship to structure of the enzyme. Arthritis Rheumatism 1999; 42(6): 1140-1146.
164. Garcia RA, Pantazatos DP, Gessner CR, Go KV, Woods VL, Villarreal FJ, et al. Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated bydeuterium exchange mass spectrometry. Mol Pharmacol 2005; 67(4): 1128-1136.
165. Yu LP, Smith GN, Hasty KA, Brandt KD. Doxycycline inhibits type XI collagenolytic activity of extracts from human osteoarthritic cartilage and of gelatinase. J Rheumatol 1991; 18(10): 1450-1452.
166. Lauhio A, Konttinen YT, Salo T, Tschesche H, Nordström D, Lähdevirta J, et al. The in vivo effect of doxycycline treatment on matrix metalloproteinases in reactive arthritis. Ann NY Acad Sci 1994; 732: 431-432.
167. Lindy O, Konttinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A, et al. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum 1997; 40(8): 1391-1399.
168. Shlopov BV, Smith GN, Cole AA, Hasty KA. Differential patterns of response to doxycycline and transforming growth factor beta1 in the down-regulation of collagenases in osteoarthritic and normal human chondrocytes. Arthritis Rheum 1999; 42(4): 719-727.
169. Golub LM, Sorsa T, Lee HM, Ciancio S, Sorbi D, Ramamurthy NS, et al. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J Clin Periodontol 1995; 22(2): 100-109.
170. Golub LM, McNamara TF, Ryan ME, Kohut B, Blieden T, Payonk G, et al. Adjunctive treatment with subantimicrobial doses of doxycycline: Effects on gingival fluid collagenase activity and attachment loss in adult periodontitis. J Clin Periodontol 2001; 28(2): 146-156.
171. Siemonsma MA, de Hingh IH, de Man BM, Lomme RM, Verhofstad AA, Hendriks T, et al. Doxycycline improves wound strength after intestinal anastomosis in the rat. Surgery 2003; 133(3): 268-276.
172. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006; 58(2): 256-265.
173. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988; 15(6): 355-366.
174. Dimmling T, Vanderbeke O. Pharmacokinetics after oral and intravenous administration of tetracycline compounds (author's transl). Med Klin 1975; 70(7): 279-285.
175. Welling PG, Koch PA, Lau CC, Craig WA. Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects. Antimicrob Agents Chemother 1977; 11(3): 462-469.
176. Adadevoh BK, Ogunnaike IA, Bolodeoku JO. Serum levels of doxycycline in normal subjects after a single oral dose. Br Med J 1976; 1(6014): 880.
177. Gnarpe H, Dornbusch K, Hagg O. Doxycycline concentration levels in bone, soft tissue and serum after intravenous infusion of doxycycline. A clinical study. Scand J Infect Dis 1976; (Suppl 9): 54-57.
178. Alestig K. Studies on doxycycline during intravenous and oral treatment with reference to renal function. Scand J Infect Dis 1973; 5(3): 193-198.
179. Steigbigel NH, Reed CW, Finland M. Absorption and excretion of five tetracycline analogues in normal young men. Am J Med Sci 1968; 255: 296-312.
180. Ylitalo P, Hinkka H, Neuvonen PJ. Effect of exercise on the serum level and urinary excretion of tetracycline, doxycycline and sulphamethizole. Eur J Clin Pharmacol 1977; 12(5): 367-373.
181. Heaney D, Eknoyan G. Minocycline and doxycycline kinetics in chronic renal failure. Clin Pharmacol Ther 1978; 24(2): 233-239.
182. Campistron G, Coulais Y, Caillard C, Mosser J, Pontagnier H, Houin G, et al. Pharmacokinetics and bioavailability of doxycycline in humans. Arzneimittelforschung 1986; 36(11): 1705-1707.
183. Burns FR, Stack MS, Gray RD, Paterson CA. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci 1989; 30(7): 1569-1575.
184. Nicolescu AC, Holt A, Kandasamy AD, Pacher P, Schulz R. Inhibition of matrix metalloproteinase-2 by PARP inhibitors. Biochem Biophys Res Commun 2009; 387(4): 646-650.
185. Stechmiller J, Cowan L, Schultz G. The role of doxycycline as a matrix metalloproteinase inhibitor for the treatment of chronic wounds. Biol Res Nurs 11(4): 336-344.
186. Beck JD, Elter JR, Heiss G, Couper D, Mauriello SM, Offenbacher S, et al. Relationship of periodontal disease to carotid artery intimamedia wall thickness: The atherosclerosis risk in communities (ARIC) study. Arterioscler Thromb Vasc Biol 2001; 21(11): 1816-1822.
187. Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR, Papapanou PN, et al. Relationship between periodontal disease, tooth loss, and carotid artery plaque: the oral infections and vascular disease epidemiology study (INVEST). Stroke 2003; 34(9): 2120-2125.
188. Schillinger T, Kluger W, Exner M, Mlekusch W, Sabeti S, Amighi J, et al. Dental and periodontal status and risk for progression of carotid atherosclerosis: The inflammation and carotid artery risk for atherosclerosis study dental sub study. Stroke 2006; 37(9): 2271-2276.
189. Geismar K, Stoltze K, Sigurd B, Gyntelberg F, Holmstrup P. Periodontal disease and coronary heart disease. J Periodontol 2006; 77(9): 1547-1554.
190. Schaar JA, Muller JE, Falk E, Virmani R, Fuster V, Serruys PW, et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J 2004; 25(12): 1077-1082.
191. Mosorin M, Juvonen J, Biancari F, Satta J, Surcel HM, Leinonen M, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: A randomized, double-blind, placebocontrolled pilot study. J Vasc Surg 2001; 34(4): 606-610.
192. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003; 23(3): 483-488.
193. Axisa B, Loftus IM, Naylor AR, Goodall S, Jones L, Bell PR, et al. Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 2002; 33(12): 2858-2864.
194. Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM. Doxycycline modulates smooth muscle cell growth, migration, andmatrix remodeling after arterial injury. Am J Pathol 2002; 160(3): 1089-1095.
195. Madan M, Bishayi B, Hoge M, Messas E, Amar S. Doxycycline affects diet- and bacteria-associated atherosclerosis in an ApoE heterozygote murine model: Cytokine profiling implications. Atherosclerosis 2007;190(1): 62-72.
196. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004; 24(4): 733-738.
197. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: Relation to ventricular and myocyte function. Circ Res 1998; 82(4): 482-495.
198. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem 1996; 155(1):13-21.
199. Cleutjens JP. The role of matrix metalloproteinases in heart disease. Cardiovasc Res 1996; 32(5): 816-821.
200. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997; 386(6625): 616-619.
201. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemiareperfusion injury in the heart. Circulation 2000; 101(15): 1833-1839.
202. Matturri L, Cazzullo A, Turconi P, Roncoroni L, Grana D, Milei J. Inflammatory cells, apoptosis and Chlamydia pneumoniae infection in atherosclerosis. Int J Cardiol 2000; 75(1): 23-33; discussion 33-25.
203. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, et al. Azithromycin for the secondary prevention of coronary heart disease events: The WIZARD study: A randomized controlled trial. JAMA 2003; 290(11): 1459-1466.
204. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352(16): 1637-1645.
205. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 352(16):1646-1654.
206. Smith K, Leyden JJ. Safety of doxycycline and minocycline: A systematic review. Clin Ther 2005; 27(9): 1329-1342.
207. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997; 133(10): 1224-1230.
208. Eriksson, A., Lepistö, M., Lundkvist, M., Munck, A.R.M., Zlatoidsky, P. Metalloproteinase inhibitors. US7427631 (2008) &US7666892 (2010).
209. Tucker, H. Inhibitors of metalloproteinases. US6916817 (2005).
210. Henriksson, K., Henriksson, K.H. 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12. US7354940 (2010).
211. Fujimoto, R.A., McQuire, L.W., Monovich, L.G., Nantermet, P., Parker, D.T., Robinson, L.A., Skiles, J.W., Tommasi, R.A., Novartis A.G. Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors. WO2009072577 (2009).
212. Sawada, A., Neya, M. MMP Inhibitor. WO2002030873 (2002).
213. Pusateri, E.E., Tommasi, R.A., Leutert, T., Grob, J.E., Honda, A., Novartis, A.G. Selective hydroxamate based MMP inhibitors. WO2007117981 (2007).
214. Schwartz, M.A., Jin, Y., Sang, Q.X. Susbtituted heterocyclic mercaptosulfonamide metalloprotease inhibitors. WO2010028051 (2010).
215. McQuire, L.W., Rogel, O., Shultz, M., Tommasi, R.A., Weiler, S. Novartis, A.G. Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors. WO2010007027 (2010).
216. Fryer, A.M., Rizzi, J. Alkylsulfonamide-substituted triazoles as matrix metalloprotease inhibitors. US20100234378 (2010).
217. Sheppeck, J.E., Duan, J., Xue, C.-B., Wasserman, Z. Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE). US6906053 (2005).
218. Bird, J., Montana, J.G., Wills, R.E., Baxter, A.D., Owen, D.A. Selective MMP inhibitors having reduced side-effects. US6818622 (2004).
219. Wallach, S., Sameah-greenwald, S., Novik, A., Tsypkin, E., Nemzer, S. Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis. US20100261169 (2010).
220. Barta, T.E., Becker, D.P., Boehm, T.L., Decrescenzo, G.A., Willami1, C.I., Mcdonald, J.J., Freskos, J.N., Getman, D.P., Hanson, G.J. Aromatic sulfone hydroxamic acid metalloproteaseinhibitor. US20020039287 (2002).
221. Schotzinger, R.J. Metallo-hydrolase inhibitors using metal binding moietes in combination with targeting moieties. US20100256082 (2010).